Mithila Samachar

PARP Inhibitors Pipeline Insights and Report 2021

 Breaking News
  • No posts were found

PARP Inhibitors Pipeline Insights and Report 2021

November 08
20:06 2021
PARP Inhibitors Pipeline Insights and Report 2021

DelveInsight’s, “PARP Inhibitors Pipeline Insights, 2021,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in PARP Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

PARP Inhibitors Overview

PARP is a family of proteins loosely based on structural similarity and function. PARP proteins are composed of two ribose moieties and two phosphates per unit polymer. PARP1 and PARP2 are enzymes involved in a DNA repair pathway for SSBs called BER. The best-known PARP is PARP1. This enzyme was first reported in 1963. In 1980 Durkacz et al. proposed that modulating PARP1 might augment the effect of alkylator chemotherapy.

 

Download Sample ReportPARP Inhibitors Market Pipeline

 

PARP Inhibitors Companies

  • TESARO
  • AstraZeneca
  • Sun BioPharma
  • Eisai Co
  • BeiGene
  • IMPACT Therapeutics
  • Ribon Therapeutics

 

PARP Inhibitors Pipeline Report

This segment of the PARP Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

PARP Inhibitors Emerging Drugs

Pamiparib: BeiGene

Pamiparib (BGB-290) is an investigational small molecule inhibitor of PARP1 and PARP2. Pamiparib is being evaluated as a monotherapy in pivotal clinical trials in China in recurrent platinum-sensitive and BRCA1/2 mutated ovarian cancers. It is currently in global clinical development as a monotherapy, and in combination with other agents, including BeiGene’s investigational anti-PD1 antibody, tislelizumab (BGB-A317), for a variety of solid tumor malignancies.

 

PARP Inhibitors Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses PARP Inhibitors therapeutic drugs key players involved in developing key drugs.

 

PARP Inhibitors Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging PARP Inhibitors drugs.

 

Request Sample ReportPARP Inhibitors Pipeline Insights

 

Table of content

  • Introduction
  • Executive Summary
  • PARP Inhibitors: Overview
  • Pipeline Therapeutics
  • Therapeutic Assessment
  • PARP Inhibitors – DelveInsight’s Analytical Perspective
  • In-depth Commercial Assessment
  • PARP Inhibitors Collaboration Deals
  • Late Stage Products (Phase III)
  • Pamiparib: BeiGene
  • Mid Stage Products (Phase II)
  • Drug Name: Company Name
  • Pre-clinical and Discovery Stage Products
  • Drug Name: Company Name
  • Inactive Products
  • PARP Inhibitors Key Companies
  • PARP Inhibitors Key Products
  • PARP Inhibitors- Unmet Needs
  • PARP Inhibitors- Market Drivers and Barriers
  • PARP Inhibitors- Future Perspectives and Conclusion
  • PARP Inhibitors Analyst Views
  • PARP Inhibitors Key Companies
  • Appendix

 

PARP Inhibitors Pipeline Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence PARP Inhibitors R&D. The therapies under development are focused on novel approaches for PARP Inhibitors.
  • July 2020: Oncology Venture announced that it has secured the remaining ownership in its priority PARP inhibitor (2X-121) program along with its 2X-111 program, by acquiring all outstanding shares in Oncology Venture US Inc. (formerly 2X Oncology, Inc.) from its external shareholders and warrantholders. As a result of the transaction, the Company now has 100 % ownership of 2X-121, which is being clinically developed as an anti-cancer therapeutic, as well as being tested as an anti-viral agent against COVID-19. Similarly, the Company now has 100% ownership of 2X-111, which is being clinically developed as an anti-cancer therapeutic via a recently announced license agreement with Smerud Medical Research International.

 

About DelveInsight

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

 

Contact Us

Yash

[email protected]

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/